MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection

Carcinogenesis

Volumn 29, Issue 6, 2008, Pages 1192-1196

  Yoon, Young Joon ^a,b   Chang, Hye Young ^a,b   Ahn, Sang Hoon ^a,b   Kim, Ja Kyung ^a,b   Park, Yong Kwang ^b,c   Kang, Dae Ryong ^d   Park, Jun Yong ^a,b   Myoung, Sung Min ^a,b   Kim, Do Young ^a,b   Chon, Chae Yoon ^a,b   Han, Kwang Hyub ^a,b  

^a Yonsei University College of Medicine   (South Korea)

^b Liver Cirrhosis Clinical Research Center   (South Korea)

^c Yonsei University   (South Korea)

^d Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; ARGININE; PROLINE; PROTEIN MDM2; PROTEIN P53; VIRUS DNA;

ADULT; ALCOHOL CONSUMPTION; AMINO ACID SUBSTITUTION; ARTICLE; CANCER RISK; CARCINOGENESIS; CODON; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; KOREA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; ONSET AGE; PRIORITY JOURNAL; PROMOTER REGION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM;

AGE OF ONSET; CARCINOMA, HEPATOCELLULAR; FEMALE; GENES, P53; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HEPATITIS B, CHRONIC; HUMANS; KOREA; LIVER NEOPLASMS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS C-MDM2;

EID: 47049091199     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgn090     Document Type: Article

References (49)

1. Parkin,D.M. et al. (2001) Estimating the world cancer burden: globocan 2000. Int. J. Cancer, 94, 153-156.
2. Marrero,J.A. (2006) Hepatocellular carcinoma. Curr Opin. Gastroenterol., 22, 248-253.
3. Sherman,M. (2005) Hepatocellular carcinoma: Epidemiology, risk factor, and screening. Semin. Liver Dis., 25, 143-154.
4. Collier,J. et al. (1998) Screening for hepatocellular carcinoma. Hepatology, 27, 273-278.
5. Chan,H.L. et al. (2006) Hepatocellular carcinoma and hepatitis B virus. Semin. Liver Dis., 26, 153-161.
6. Han,K.H. et al. (2005) How to predict HCC development ill patients with chronic B viral liver disease? Intervirology, 48, 23-28.
7. Tong,M.J. et al. (2007) Basal core promoter T1762/A1764 and precore A1896 gene mutations in hepatitis B surface antigen-positive hepatocellular carcinoma: A comparison with chronic carriers. Liver Inc., 27, 1356-1363.
8. Yu,M.W. et al. (2005) Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: A prospective study in men. J. Natl Cancer Inst., 97, 265-272.
9. Mahmood,S. et al. (2005) Influence of viral load and genotype in the progression of Hepatitis B-associated liver cirrhosis to hepatocellular carcinoma. Liver Int., 25, 220-225.
10. Nissen,N.N. et al. (2002) Hepatocellular carcinoma: The high-risk patient. J. Clin. Gastroenterol., 35, S79-S85.
11. Kim,Y.J. et al. (2005) Single nucleotide polymorphisms associated with hepatocellular carcinoma with chronic hepatitis B virus infection. Intervirology, 48, 10-15.
12. Yu,M.W. et al. (2003) Polymorphism in XRCC1 and glutathione S-transferase genes and hepatitis B-related hepatocellular carcinoma. J Natl Cancer Inst., 95, 1485-1488.
13. Zhu,Z.Z. et al. (2005) Homozygosity for Pro of p53 Arg72Pro as a potential risk factor for hepatocellular carcinoma in Chineses population. World J. Gastroenterol., 11, 289-292.
14. Ahn,S.H. et al. (2000) Association between hepatitis B virus infection and HLA-DR type in Korea. Hepatology, 31, 1371-1373.
15. Ahn,S.H. et al. (2006) Association of genetic variations in CCR5 and its ligand, RANTES with clearance of hepatitis B virus in Korea. J. Med. Virol., 78, 1564-1571.
16. Park,S.R. et al. (2006) MDM2 309T G polymorphism and risk of lung cancer in a Korean population. Lung Cancer, 54, 19-24.
17. Bougeard,G. et al. (2006) Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome. J. Med. Genet., 43, 531-533.
18. Zhang,X. et al. (2006) Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. Hum. Mutat., 27, 110-117.
19. Bond,G.L. et al. (2004) A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell, 119, 591-602.
20. Dharel,N. et al. (2006) NOM2 promoter SNP309 is associated with the risk of hepatocellular carcinoma in patients with chronic hepatitis C. Clin. Cancer Res., 12, 4867-4871.
21. Staib,F. et al. (2003) TP53 and liver carcinogenesis. Hum Mutat., 21, 201-216.
22. Thomas,M. et al. (1999) Two polymorphic variants of wild-type TP53 differ biochemically and biologically. Mol. Cell. Biol., 19, 1092-1100.
23. Dumont,P. et al. (2003) The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat. Genet., 33 357-365.
24. Yu,M.W. et al. (1999) A p53 genetic polymorphism as a modulator of hepatocellular carcinoma risk in relation to chronic liver disease, familial tendency, and cigarette smoking in hepatitis B carriers. Hepatology, 29, 697-702.
25. Zhu,Z.Z. et al. (2005) A p53 polymorphism modifies the risk of hepatocellular carcinoma among non-carriers but not carriers of chronic hepatitis B virus infection. Cancer Lett., 229, 77-83.
26. Talseth,B.A. et al. (2006) NMM2 SNP T G alone or in combination with TP53 R72P polymorphism does not appear to influence disease expression and age of diagnosis of colorectal cancer in HNPCC patients. Int. J. Cancer, 120, 563-565.
27. Lee,J.M. et al. (2004) Reappraisal of HBV genotypes and clinical significance in Koreans using MALDI-TOF mass spectrometry. Korean J. Hepatol., 10, 260-270.
28. Walsh,C.S. et al. (2007) Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk. Gynecol. Oncol., 104, 660-664.
29. Ohmiya,N. et al. (2006) MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. J. Clin. Oncol., 24, 4434-4440.
30. Alhopuro,P. et al. (2005) The MDM2 promoter polymorphism SNP309T→G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck. J. Med Genet., 42, 694-698.
31. Hong,Y. et al. (2005) The role of p53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer Res., 65 9582-9587.
32. Hu,Z. et al. (2005) Genetic variants in the MDM2 promoter and lung cancer risk in a Chinese population. Int. J. Cancer, 118, 1275-1278.
33. Ma,H. et al. (2006) Polymorphisms in the MDM2 promoter and risk of breast cancer: A case-control analysis in a Chinese population. Cancer Lett., 240, 261-277.
34. Millikan,R.C. et al. (2006) No association between the MDM2-309T/G promoter polymorphism and breast cancer in African-Americans or Whites. Cancer Epidemiol. Biomarkers Prev., 15, 175-177.
35. Li,G. et al. (2006) MDM2 gene promoter polymorphisms and risk of lung cancer: A case-control analysis. Carcinogenesis, 27, 2028-2033.
36. Lind,H. et al. (2006) Association of a functional polymorphisms in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer. Int. J. Cancer, 119, 718-721.
37. Matakidou,A. et al. (2003) TP53 polymorphisms and lung cancer risk: A systemic review and meta analysis. Mutagenesis, 18, 377-385.
38. Anzola,M. et al. (2003) Frequent loss of p53 codon 72 Pro variant in hepatitis C virus-positive carriers with hepatocellular carcinoma. Cancer Lett., 193, 199-205.
39. Hiyama,T. et al. (2002) p53 codon 72 polymorphism in gastric cancer susceptibility in patients with Helicobacter pylori associated chronic gastritis. Int. J. Cancer, 100, 304-308.
40. Irarrazabal,C.E. et al. (2003) Chilean pilot study on the risk of lung cancer associated with codon 72 polymorphism in the gene of protein p53. Toxicol. Lett., 144, 69-76.
41. Lee,J.M. et al. (2000) Genetic polymorphisms of p53 and GSTP1, but not NAT2, are associated with susceptibility to squamous cell carcinoma of the esophagus. Int. J. Cancer, 89, 458-464.
42. Sjalander,A. et al. (1996) p53 polymorphsms and haplotypes in breast cancer. Carcinogenesis, 17, 1313-1316.
43. Suzuki,K. et al. (2003) A p53 codon 72 polymorphism associated with prostate cancer development and progression in Japanese. J. Biomed. Sci., 10, 430-435.
44. Tsai,M.H. et al. (2002) Prognostic significance of the praline form of p53 codon 72 polymorphism in nasopharyngeal carcinoma. Laryngoscope, 112, 116-119.
45. Chen,C.J. et al. (1996) Elevated aflatoxin exposure and increased risk of hepatocellular carcinoma. Hepatology, 24, 38-42.
46. Llovet,J.M. et al. (2003) Hepatocellular carcinoma. Lancet, 362, 1907-1917.
47. Tang,Z.Y. (2001) Hepatocellular carcinoma-Cause, treatment and metastasis. World J. Gastroenterol., 7, 445-454.
48. Yuen,M.F. et al. (2005) Serological markers of liver cancer. Best Pract. Res. Clin. Gastroenterol., 19, 91-99.
49. Chen,J. et al. (1996) Mdm-2 inhibits the G1 arrest and apoptosis function of the TP53 tumor suppressor protein. Mol. Cell. Biol., 16, 2445-2452.